COMPANY PROFILE

Sermonix Pharmaceuticals

Explore full profile

Ohio llc specialty pharmaceutical

Columbus, United StatesFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Sermonix Pharmaceuticals

Sermonix Pharmaceuticals, founded in 2014 by Dr. David Portman, is a privately held biotechnology company based in Ohio. The company specializes in the development and commercialization of oncology products specifically for women. Sermonix focuses on precision medicine, aiming to bring targeted oncology treatments from development through to approval. The company is currently investigating lasofoxifene, a compound extensively studied for its potential in treating breast and ovarian cancers. Sermonix serves the oncology market, particularly targeting postmenopausal women and premenopausal women undergoing ovarian suppression. The business model involves conducting clinical trials, such as the ELAINE Study, to evaluate the efficacy of their treatments. Revenue is generated through the development and eventual commercialization of these targeted therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Columbus, United States
Open positions: None listed
Dealroom signal: 22.0/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Nov 2021	$40M	$160M	Xontogeny · Perceptive Advisors	↗
SERIES AOther financing	Jul 2019	$26M	$104M	Wild Family Office	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Sermonix Pharmaceuticals website traffic

Latest recorded traffic for Sermonix Pharmaceuticals is 2.4K monthly website visits, up 71.4% over the last three months.

Latest monthly visits2.4K 3-month web change+71.4%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational	7	$2.1M	$8.4M
SISPES Pharmaceuticals Inc.The company focuses on the research and development of improved specialty injectable products 505(b)(2)and complex generic drugs	United States	Operational
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
VBVincere BiosciencesVincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD)	Cohasset, United States	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
APApoGlyxDeveloping new therapeutic concepts for metabolic and inflammatory diseases with innovative and proprietary Aquaporin technology	Lund Municipality, Sweden	Operational
RERenovosNanoclay gel platform for regenerative medicine therapeutics	Chilworth, United Kingdom	Operational